Premium
Retrospective analysis of the clinical characteristics of adefovir dipivoxil–induced Fanconi’s syndrome in the Chinese population
Author(s) -
Sun Linli,
Yi Dan,
Sun Wei,
Wang Chunjiang
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13154
Subject(s) - adefovir , fanconi syndrome , medicine , hypophosphatemia , population , gastroenterology , pediatrics , chronic hepatitis , immunology , environmental health , kidney , virus , lamivudine
What is known and objective To explore the clinical characteristics of adefovir dipivoxil–induced Fanconi's syndrome in the Chinese population and provide a reference for rational drug use in the clinic. Methods By searching the CNKI, Wanfang, Chinese VIP, PubMed/MEDLINE, Web of Knowledge, Ovid, Elsevier and SpringerLink databases during 1 January 2008 to 31 December 2019, 78 studies of ADV‐induced Fanconi's syndrome involving a total of 110 patients were collected and analysed retrospectively. Results and discussion Prolonged usage of adefovir dipivoxil at low doses to treat hepatitis B might cause Fanconi's syndrome as the first symptom, especially for use over 12 months.The main clinical manifestation was bone pain accompanied by hypophosphataemia, elevated alkaline phosphatase (ALP), urine glycosuria and urine protein. X‐rays and bone mineral density (BMD) examinations were mainly used to characterized osteoporosis. The patients had pain relief within 1 week to 1 month, and the biochemical indicators returned to normal within from 2 to 4 months. What is new and conclusion Sufficient attention is required before and during exposure to long‐term ADV therapy. The clinical picture, laboratory and radiograph alterations are important clues for ADV‐induced Fanconi's syndrome.